Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells
- PMID: 16982772
- DOI: 10.1158/0008-5472.CAN-06-1758
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells
Erratum in
-
Correction: Combined Depletion of Cell Cycle and Transcriptional Cyclin-Dependent Kinase Activities Induces Apoptosis in Cancer Cells.Cancer Res. 2020 Jan 15;80(2):361. doi: 10.1158/0008-5472.CAN-19-3524. Cancer Res. 2020. PMID: 31941678 No abstract available.
Abstract
Selective cyclin-dependent kinase (cdk) 2 inhibition is readily compensated. However, reduced cdk2 activity may have antiproliferative effects in concert with other family members. Here, inducible RNA interference was used to codeplete cdk2 and cdk1 from NCI-H1299 non-small cell lung cancer and U2OS osteosarcoma cells, and effects were compared with those mediated by depletion of either cdk alone. Depletion of cdk2 slowed G1 progression of NCI-H1299 cells and depletion of cdk1 slowed G2-M progression in both cell lines, with associated endoreduplication in U2OS cells. However, compared with the incomplete cell cycle blocks produced by individual depletion, combined depletion had substantial consequences, with G2-M arrest predominating in NCI-H1299 cells and apoptosis the primary outcome in U2OS cells. In U2OS cells, combined depletion affected RNA polymerase II expression and phosphorylation, causing decreased expression of the antiapoptotic proteins Mcl-1 and X-linked inhibitor of apoptosis (XIAP), effects usually mediated by inhibition of the transcriptional cdk9. These events do not occur after individual depletion of cdk2 and cdk1, suggesting that reduction of cdk2, cdk1, and RNA polymerase II activities all contribute to apoptosis in U2OS cells. The limited cell death induced by combined depletion in NCI-H1299 cells was significantly increased by codepletion of cdk9 or XIAP or by simultaneous treatment with the cdk9 inhibitor flavopiridol. These results show the potency of concomitant compromise of cell cycle and transcriptional cdk activities and may guide the selection of clinical drug candidates.
Similar articles
-
AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.Cancer Res. 2006 Jan 1;66(1):435-44. doi: 10.1158/0008-5472.CAN-05-1769. Cancer Res. 2006. PMID: 16397259
-
Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line.Int J Oncol. 1999 Jul;15(1):161-6. Int J Oncol. 1999. PMID: 10375610
-
Growth inhibition and induction of apoptosis by flavopiridol in rat lung adenocarcinoma, osteosarcoma and malignant fibrous histiocytoma cell lines.Oncol Rep. 2004 May;11(5):1025-30. Oncol Rep. 2004. PMID: 15069542
-
Cyclin-dependent kinase pathways as targets for cancer treatment.J Clin Oncol. 2006 Apr 10;24(11):1770-83. doi: 10.1200/JCO.2005.03.7689. J Clin Oncol. 2006. PMID: 16603719 Review.
-
Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1.Cell Cycle. 2016 May 2;15(9):1184-8. doi: 10.1080/15384101.2016.1160983. Epub 2016 Mar 17. Cell Cycle. 2016. PMID: 26986210 Free PMC article. Review.
Cited by
-
Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.Mol Cancer Ther. 2016 Nov;15(11):2758-2766. doi: 10.1158/1535-7163.MCT-16-0127. Epub 2016 Aug 22. Mol Cancer Ther. 2016. PMID: 27550941 Free PMC article.
-
Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.Acta Pharmacol Sin. 2016 Nov;37(11):1481-1489. doi: 10.1038/aps.2016.49. Epub 2016 Aug 29. Acta Pharmacol Sin. 2016. PMID: 27569395 Free PMC article.
-
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.Ann Oncol. 2010 Apr;21(4):884-894. doi: 10.1093/annonc/mdp377. Epub 2009 Oct 13. Ann Oncol. 2010. PMID: 19825886 Free PMC article. Clinical Trial.
-
APC/C--the master controller of origin licensing?Cell Div. 2007 Feb 23;2:8. doi: 10.1186/1747-1028-2-8. Cell Div. 2007. PMID: 17319958 Free PMC article.
-
The formation of tight tumor clusters affects the efficacy of cell cycle inhibitors: a hybrid model study.J Theor Biol. 2014 Jul 7;352:31-50. doi: 10.1016/j.jtbi.2014.02.027. Epub 2014 Mar 5. J Theor Biol. 2014. PMID: 24607745 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
